The in vitro activities of mecillinam, a new f)-amidinopenicilhin, and ampicillin, alone and in combination, against an Escherichia coli strain and a Klebsiella pneumoniae strain were compared, and these results were correlated with their respective activities in vivo in experimental meningitis. The mecillinam-ampicillin combination was synergistic in vitro against both strains when tested by a modified checkerboard technique (bacteriostatic synergy). However when quantitative bactericidal synergy studies were made, the relative bactericidal rate of the combination was more rapid than that of either drug alone ("bactericidal synergy") against the Escherichia coli isolate only. In a rabbit model of Enterobacteriaceae meningitis, in vivo bactericidal activity correlated with results obtained in vitro. Both drugs were administered by continuous intravenous infusion for 8 h. Serum and cerebrospinal fluid antibiotic levels were similar to those achieved in humans. Cerebrospinal fluid bacterial concentrations (colonyforming units [CFU] per milliliter) were quantitatively titrated at 2-h intervals. Both drugs, alone or the combination, were ineffective against the K. pneumoniae strain in vivo (change in titer <1 log in 8 h). In contrast, the combination produced a markedly enhanced bactericidal effect against the E. coli strain (mean + standard deviation, decrease of log1o CFU per milliliter of 3.65 ± 1.02) compared with those of ampicillin alone (decrease of log1o CFU per milliter of 0.07 ± 0.8) and mecillinam alone (decrease of logio CFU per milliliter of 1.6 ± 0.05) (P < 0.001). When bactericidal synergism can be demonstrated for mecillinam-ampicillin in vitro in a case of gram-negative-bacillary meningitis this combination may be useful in the therapy of the illness.
Gram-negative-bacillary meningitis is an uncommon but devastating form of central nervous system infection. Most cases of neonatal or postneurosurgical meningitis are now caused by the Enterobacteriaceae or Pseudomonas (7, 9, 11) . The mortality rate and frequency of neurological sequelae remain high (2, 17) . Depressed host defenses, pathogenicity of the infecting organisms, foreign body placement, or numerous surgical procedures may all contribute to the poor therapeutic results (12, 13) . In addition, antimicrobial therapy is difficult to administer and often ineffective. Most infecting strains are now resistant to ampicillin (12) , and chloramphenicol has only a bacteriostatic effect. Since antibody and complement-mediated opsonic activity are absent in the cerebrospinal fluid (CSF) in bacterial meningitis (M. S. Simberkoff, N. H. Moldover, and J. J. Rahal, Abstr. Clin. Res. 27: 356A, 1979), bacteriostatic antibiotics may be ineffective in this disease. The use of chloram. phenicol is limited further by the immature liver function of neonates and concerns with hematological toxicity. Results with either drug alone have been erratic (8, 11) . The aminoglycosides are now considered the drugs of choice for gramnegative-bacillary meningitis, but their low therapeutic index and poor penetration into the CSF have necessitated direct instillation of these drugs into the CSF by either the lumbar or the ventricular route. The high rate of ventriculitis in these infections, especially in neonatal meningitis (3, 9) , and the inability of gentamicin to reach ventricular sanctuaries of bacteria after intralumbar administration (8) have favored the intraventricular route. This mode of therapy notwithstanding, the mortality and complication rates remain high (13) .
Mecillinam is a new ,8-amidinopenicillin with a unique mode of action (6, 18) and a wide in vitro spectrum of activity, especially against the Enterobacteriaceae (4, 10, 19) . In addition, this agent displays synergy at very low concentrations with other beta-lactam antibiotics against members of this family in vitro (1, 6, 16, 26 Quantitative bactericidal studies were also performed in NIH broth. A dilution of an overnight culture of the test strain to give an inoculum of 105 CFU/ml was added to NIH broth in 25-ml cottonstoppered flasks. When Klebsiella was the indicator, ampicillin (5 jg/ml), mecillinam (5 or 1 yg/ml), and various combinations of the two drugs were added.
The combinations kept the ampicillin concentration constant (5 ,ug/ml) but varied the mecillinam concentration to achieve ratios of 10:1, 5:1, 3:1, 2:1, 1:1, and 1:5. When E. coli was the test species, the following concentrations were used (in micrograms per mililiter): ampicillin, 0.5; mecillinam, 0.1; or ampicillin, 0.5, plus mecillinam, 0.1. All flasks were incubated at 370C in 5% CO2 (or ambient air, with similar results) and continuously shaken. Samples were removed at 4, 8, 24 , and 48 h and quantitatively cultured on tryptic soy agar (Difco) pour plates. These quantitative bactericidal studies were run in duplicate with essentially identical results. The criterion for synergism was a >2-log reduction in bacterial concentration at any of the time points sampled, when compared with the most active agent alone.
Animal model. The test organisms were grown overnight in tryptic soy broth, centrifuged at 3,000 rpm for 15 min, suspended in saline, and diluted to ensure a final inoculum of 105 CFU. Meningitis was produced in 2-to 3-kg New Zealand white rabbits as described previously (21, 24 Arterial blood samples (3 ml) and simultaneous CSF samples (0.2 ml) were collected at 0, 2, 4, 6, and 8 h of therapy. The CSF samples were cultured quantitatively with serial 10-fold dilutions in 0.9% NaCl and tryptic soy agar pour plates. The remainder of the CSF sample and the serum samples were kept at -70°C until antibiotic assays were done (within 2 weeks). This period of storage did not affect the assay results.
Antibiotic assays. Antibiotic concentrations were determined with agar well diffusion techniques. A Bacillus subtilis (control no. 640925; Difco) spore suspension (0.2 ml) was added to 100 ml of antibiotic medium no. 1 (adjusted to pH 6.0), poured into plates, and used for ampicillin level determinations. An ampicillin-resistant E. coli (Leo Ha2, kindly provided by Hoffman-La Roche) was used as the indicator strain for determination of mecillinam concentrations. This strain was maintained on slants of antibiotic medium ,no. 1 containing 100 ug of ampicillin per ml and transferred at weekly intervals. A fresh slant was inoculated the day before the assay and incubated at 340C for 16 to 18 h. The growth was washed from the slants with 3 to 5 ml of sterile saline and adjusted to 90% transmittance at 650 nm on a Gould spectrophotometer. This adjusted suspension (20 ml) was added to 1,000 ml of antibiotic medium no. 1 and poured into plates. All assays were done in triplicate in 150-mm-diameter plates with an agar depth of 5 The MBCs obtained in NIH broth for the E. coli strain were 2 and 4 ug/ml for mecillinam and ampicillin, respectively, levels which are potentially achievable within infected CSF in vivo. In contrast to results with the K. pneumoniae strain, where only inhibitory synergism was demonstrable, an enhanced bactericidal effect ("bactericidal synergism") was observed for this E. coli strain in time-kill experiments in NIH broth (Fig. 1) . The mean initial bacterial titer was logio 6.457 ± 0.023 (standard deviation) CFU/ml. Ampicillin (0.5 ,Lg/ml) did not reduce bacterial titers when compared with control flasks at 4 and 24 h of incubation, and the final titer was essentially the same as the initial titer (loglo 6.301 ± 0.069 CFU/ml). Mecillinam (0.1 Ag/ml) reduced bacterial titers by approximately 4 logs at 24 h, but titers increased over 2 logs between 24 and 48 h (Fig. 1) (12, 14, 27) . The CSF levels reached steady states by 2 h and were reproducible between animals ( Table 2 ). The mean (± standard deviation) CSF concentrations were 0.8 ± 0.5 and 2.6 ± 1. 4 .g/ml for ampicillin and mecillinam, respectively. Despite virtually identical serum levels, mecillinam, achieved higher CSF levels than did ampicillin. The percent penetration, defined as the CSF concentration expressed as a percentage of the concurrent serum concentration, was nearly three times higher for mecillinam when compared with ampicillin (P < 0.01).
Bacterial killing. Bacterial killing in vivo was examined in the CSF of 22 rabbits with Klebsiella meningitis and 29 rabbits with E. coli meningitis. Measurements of CFU per milliliter were made in all rabbits before and 2, 4, 6, and 8 h after initiating antibiotic therapy. Seven untreated control animals in each group exhibited slight rises in bacterial titers after 8 h (Table 3) ; all died within 48 h of inoculation. The initial bacterial titers within the CSF did not differ significantly among the three treatment regimens in either type of meningitis (Table 3 ). These initial titers were usually between 104 and 106 CFU/ml of CSF. Bacterial killing was reproducible with each regimen despite slight variability in the initial bacterial titer.
None of the three regimens used produced a bactericidal effect in experimental Klebsiella meningitis (Table 3) . Bacterial titers decreased more than 1 log in only one animal, and there were no significant differences between drug regimens with either agent alone or the combination. Thus, enhanced bactericidal activity was not demonstrable either in vivo or in vitro for this strain at the drug concentrations studied.
Ampicillin also failed to reduce bacterial titers when compared with untreated rabbits in E. coli meningitis (decrease of logio 0.07 CFU/ml in 8 h) ( Table 3 ). The bactericidal activity of mecillinam (decrease of log1o 1.59 CFU/ml in 8 h) was greater than that of ampicillin. This may reflect the lower MBC (2 ,tg/ml for mecillinam versus 4 ,ug/ml for ampicillin) and enhanced percent penetration of the former agent into the CSF. In contrast to Klebsiella meningitis, the bactericidal activity of the combination in E. coli meningitis (decrease of log10 3.6 CFU/ml in 8 h) was far greater than that of either drug alone (P < 0.001). These results correlated with those of the in vitro studies. (18, 22) . Mecillinam demonstrates remarkable affinity for penicillin-binding protein 2 in the cytoplasmic membrane (22) .
Other beta-lactams bind to this site with very low affinity, and their primary sites of action are elsewhere. These distinct modes of action may explain why mecillinam has synergistic activity against the Enterobacteriaceae when used in combination with other beta-lactams.
E. coli and the Klebsiella-Enterobacter group are the most common causative pathogens in neonatal meningitis and post-neurosurgical meningitis in adults (11, 13, 20) . Many strains of these bacteria (including ampicillin-resistant strains) are susceptible to mecillinam in vitro. These forms of meningitis do not respond well to therapy. The mortality rate exceeds 30%, and a majority of survivors develop neurological sequelae (13) . Combinations of mecillinam with other beta-lactam antibiotics may offer some advantages. This agent is highly active against many Enterobacteriaceae strains, and its penetration across the inflamed meninges is equivalent to that of ampicillin in this experimental meningitis model (23) . Similar mean CSF ampicillin levels, of 1.2 to 2.9 ,ug/ml, have been found in humans receiving standard parenteral regimens (25) . In this study we have demonstrated that enhanced bactericidal activity can be obtained in vivo with a mecillinam-ampicillin combination only when this property is demonstrated in vitro by quantitative bactericidal synergy techniques. These results suggest that this combination may be effective when given by the parenteral route alone in gram-negative-bacillary meningitis. The dosages used in this study produced serum levels slightly lower than those usually observed in humans; therefore, higher dosages may result in increased bacterial killing in vivo without an increase in toxicity. This combination deserves further study in the treatment of gram-negative-bacillary meningitis. 
